IMM-20059
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy[1].
Product Specifications
UNSPSC
12352203
Target
Others
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
I[M][M20059]
References & Citations
[1]Fang Shen, et al. IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy. Immunome Poster at SITC Annual Meeting (November 8-12, 2022) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog